Economics Of Personalizing Breast Cancer Treatment

Cost-utility analyses of new biotechnologies are often conducted under best-practice hypotheses; there exists a need to examine the robustness of these analyses in the real-health practice setting.


Oncotype DX® (Genomic Health, Inc. Redwood City, CA), a 21-gene assay, was clinically validated as an accurate predictor of 10-year recurrence-free survival and patient's response to treatment among the early-stage estrogen-receptor-positive, lymph-node-negative breast cancer (ER+ LN- ESBC) population. Although previous cost-effective evaluations of Oncotype DX against best-practice standards have been published, a recent study, "Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization" presents the first "real-life" analysis of OncotypeDX's impact on the overall cost of care in Israel's leading managed-care system, Clalit Health Services (Tel Aviv, Israel).


This Israeli cost-effectiveness study, published in Value in Health, found that the adoption of Oncotype DX lead to a change of treatment recommendation for a significant portion of the study population. In addition, the study indicates that Oncotype DX is a cost-effective technology that favorably affects the lives of women with ESBC. The study was a collaborative effort of Clalit Health Services and Cedar Associates, LLC (Menlo Park, CA).


Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide.


Oncotype DX Breast Cancer Assay represents an economical and personalized treatment decision tool. Details of this study will be available in upcoming issue of Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research.


For further information on the clinical validity, utility and economics of Oncotype DX, please visit genomichealth.


Source
ISPOR